Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer

M. Mirowski, J. Klijanienko, S. Wang, P. Vielh, Z. Walaszek, M. Hanausek

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Sera from 132 breast cancer patients and 112 healthy female controls were tested with a double-antibody sandwich ELISA using two different monoclonal antibodies against the 65-kDa oncofetal protein, termed p65. Of cancer sera, 90.2% were positive for p65. The average level of p65 was 466.5 ± 243.8 ng/ml (mean ± S.D.) in carcinomas and 37.4 ± 29.5 ng/ml (mean ± S.D.) in controls (P < 0.0005). A selected group (n = 15) of these 132 patients were needle-biopsied and assessed immunohistochemically using monoclonal antibodies against p65. Nucleocytoplasmic expression was found in 12 patients (80%) using monoclonal antibodies. Expressions of p65 were concordant in 13 (86%) cases between serum and tumour tissues, but did not correlate with tumour DNA ploidy, histological grade or hormone receptors levels. Sera were also tested for CA 15-3 with the average value in cancer serum being 132.4 ± 14.0 U/ml; there was no significant concordance between the two markers. Thus, p65 may be a potential serum and/or immunohistochemical marker for breast carcinoma.

Original languageEnglish (US)
Pages (from-to)1108-1113
Number of pages6
JournalEuropean Journal of Cancer
Issue number8
StatePublished - 1994
Externally publishedYes


  • antibodies
  • breast cancer
  • CA 15-3
  • immunohistochemistry
  • p65

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Serological and immunohistochemical detection of a 65-kDa oncofetal protein in breast cancer'. Together they form a unique fingerprint.

Cite this